More specifically, results from the KEYNOTE-024 Phase 3 trial testing the efficacy of pembrolizumab (anti-PD-1) in non-small cell lung cancer found that males exhibited a lower hazard for disease progression (HR = 0.39, 95% CI 0.26–0.58), compared to females (HR = 0.75, 95% CI 0.46–1.21) [29]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.